Ipsen Completes Acquisition of Clementia Pharmaceuticals Apr 18, 2019 01:00AM
Clementia Pharmaceuticals (CMTA) Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen Apr 11, 2019 12:01PM
Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A. Apr 11, 2019 12:00PM
Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A. Apr 9, 2019 12:29PM
Clementia Pharmaceuticals Inc. Obtains Interim Order for Proposed Transaction With Ipsen S.A. and Enters Into Support and Voting Agreements With Two Additional Significant Shareholders Mar 7, 2019 02:55PM


Mar 7, 2019 01:00PM Clementia Pharmaceuticals Inc. obtains interim order for proposed transaction with Ipsen S.A. and enters into support and voting agreements with two additional significant shareholders
Feb 26, 2019 06:30AM Clementia Announces Cancellation of Fourth Quarter and Year-End 2018 Financial Results and Conference Call
Feb 26, 2019 06:30AM Clementia Announces Cancellation of Fourth Quarter and Year-End 2018 Financial Results and Conference Call
Feb 25, 2019 06:11AM Ipsen Announces Acquisition of Clementia Pharmaceuticals (CMTA)
Feb 25, 2019 01:00AM Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio
Feb 20, 2019 06:30AM Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healthcare Conference
Feb 20, 2019 06:30AM Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healthcare Conference
Feb 11, 2019 06:32AM Clementia (CMTA) Granted Rare Pediatric Disease Designation by FDA for Palovarotene for FOP
Feb 11, 2019 06:30AM Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
Feb 11, 2019 06:30AM Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
Nov 30, 2018 09:00AM Clementia Announces the Departure of Chief Commercial Officer
Nov 30, 2018 09:00AM Clementia Announces the Departure of Chief Commercial Officer
Nov 21, 2018 06:30AM Clementia to Present at the Evercore ISI HealthCONx Conference
Nov 21, 2018 06:30AM Clementia to Present at the Evercore ISI HealthCONx Conference
Nov 7, 2018 06:30AM Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates
Nov 7, 2018 06:30AM Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates
Oct 23, 2018 04:01PM Clementia (CMTA) to Submit a New Drug Application for Palovarotene for Treatment of FOP Based on Positive Phase 2 Results
Oct 23, 2018 04:01PM Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results
Oct 23, 2018 04:01PM Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results
Oct 2, 2018 06:30AM Clementia Pharmaceuticals (CMTA) Commences Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers
Oct 2, 2018 06:30AM Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers
Oct 2, 2018 06:30AM Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers
Sep 26, 2018 08:32AM Clementia Pharmaceuticals (CMTA) Reports Updated Phase 2 Part B Data on Palovarotene for FOP
Sep 26, 2018 08:30AM Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP
Sep 26, 2018 08:30AM Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP
Sep 5, 2018 06:30AM Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences
Sep 5, 2018 06:30AM Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences
Aug 16, 2018 06:31AM Clementia Pharmaceuticals (CMTA) Reports Complete Enrollment in Phase 3 MOVE Trial for FOP
Aug 16, 2018 06:30AM Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP
Aug 16, 2018 06:30AM Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP
Aug 9, 2018 06:30AM Clementia Reports Second Quarter 2018 Operating Results and Pipeline Updates
Aug 9, 2018 06:30AM Clementia Reports Second Quarter 2018 Operating Results and Pipeline Updates
Jul 13, 2018 06:30AM Clementia Pharmaceuticals (CMTA) Appoints Steve Forte as Chief Financial Officer
Jul 13, 2018 06:30AM Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial Officer
Jul 13, 2018 06:30AM Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial Officer
Jul 5, 2018 06:30AM Clementia Pharmaceuticals (CMTA) Announces Shawn Tomasello to Board
Jul 5, 2018 06:30AM Clementia Appoints Industry Executive Shawn Tomasello to its Board of Directors
Jul 5, 2018 06:30AM Clementia Appoints Industry Executive Shawn Tomasello to its Board of Directors
May 31, 2018 06:30AM Clementia to Present at the Jefferies 2018 Global Healthcare Conference
May 31, 2018 06:30AM Clementia to Present at the Jefferies 2018 Global Healthcare Conference
May 23, 2018 06:33AM Clementia Pharmaceuticals (CMTA) Highlights Positive Phase 2 Part B Data from Ongoing Phase 2 Clinical Trial Evaluating Palovarotene for Treatment of FOP
May 23, 2018 06:30AM Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
May 23, 2018 06:30AM Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
May 9, 2018 06:30AM Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates
May 9, 2018 06:30AM Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates